Donate

UK’s NICE Reverses Itself and Now Recommends Zytiga To Treat Men Before Chemotherapy

In a sudden reversal of its prior opinion the UK's National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Janssen’s Zytiga (abiraterone) to treat advanced prostate cancer before chemotherapy. Its prior recommendation was not to approve Zytiga. TAccording to NICE their decision to change their December 2015 recommendation follows the submission [...]

NICE Recommends Xtandi, but Not Zytiga in the Pre-Chemotherapy Stage of Advanced Prostate Cancer Treatment

NICE, which serves as a cost-effectiveness agency has said in a draft guidance that it supports the use of Xtandi (enzalutamide) in men whose prostate cancer has spread after the failure of first-line therapy (i.e. ADT), but for whom chemotherapy is not yet necessary. The agency found that Xtandi can delay the need for chemotherapy, [...]

The Twists and Turns For Provenge

It was announced today that preliminary results from the Phase II STAND trial demonstrates continued and what is described as a robust immune response with Provenge (sipuleucel-T) that continues two years after completing treatment in men with biochemically-recurrent prostate cancer (BRPC). This finding, along with data from the ongoing Phase IV registry PROCEED trial, are [...]

NICE Reverses Its Decision and Now Recommends Radium-223 (Xofigo) For Men Who Have Had Chemotherapy

According to Prostate Cancer UK The National Institute for Health and Care Excellence (NICE) has released its second draft decision on the availability of radium-223 (Xofigo). Different from the original draft this draft recommends that radium-223 be made available on the NHS for men with advanced prostate cancer that no longer responds to hormone therapy [...]

British Men Who Have Had Abiraterone Will Not Get Enzalutamide Despite Its Life Extending Abilities

British Men Who Have Had Abiraterone Will Not Get Enzalutamide Despite Its Life Extending Ability Our brothers in England hit a major snag last week as NHS placed a burdensome restriction on the use of enzalutamide (Xtandi) for men with advanced prostate cancer who have already had abiraterone (Zytiga). Because of this ridiculous decision thousands [...]

NICE Rejects Zytiga for Men Without Chemotherapy Exposure

The National Institute for Health and Care Excellence (NICE), which is Britain’s healthcare cost-effectiveness agency, has determined that abiraterone (Zytiga) was not worth giving to men with castrate resistant metastatic prostate cancer who have yet to had chemotherapy.  Unlike the FDA in the United States which rules only on a drug’s efficacy, NICE decides if [...]

Go to Top